Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Alexion Will Pay $8.4 Billion To Buy Synageva

by Lisa M. Jarvis
May 11, 2015 | A version of this story appeared in Volume 93, Issue 19

In a bid to create a rare-disease powerhouse, Alexion Pharmaceuticals is paying $8.4 billion to acquire Synageva BioPharma. The deal expands Alexion’s portfolio of drugs to treat rare metabolic diseases while also significantly expanding its pipeline. Alexion gains Kanuma, a lysosomal acid lipase deficiency treatment expected to score regulatory approval in the second half of the year; SBC-103, an enzyme replacement therapy in Phase I/II studies to treat the lysosomal storage disorder disease MPS IIIB; and four treatments in preclinical studies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.